These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 15719440)

  • 1. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation.
    Chirieac LR; Swisher SG; Ajani JA; Komaki RR; Correa AM; Morris JS; Roth JA; Rashid A; Hamilton SR; Wu TT
    Cancer; 2005 Apr; 103(7):1347-55. PubMed ID: 15719440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.
    Gu Y; Swisher SG; Ajani JA; Correa AM; Hofstetter WL; Liao Z; Komaki RR; Rashid A; Hamilton SR; Wu TT
    Cancer; 2006 Mar; 106(5):1017-25. PubMed ID: 16456809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma.
    Korst RJ; Kansler AL; Port JL; Lee PC; Kerem Y; Altorki NK
    Ann Thorac Surg; 2006 Aug; 82(2):480-4; discussion 484-5. PubMed ID: 16863749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma.
    Chirieac LR; Swisher SG; Correa AM; Ajani JA; Komaki RR; Rashid A; Hamilton SR; Wu TT
    Clin Cancer Res; 2005 Mar; 11(6):2229-36. PubMed ID: 15788671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma.
    Gaca JG; Petersen RP; Peterson BL; Harpole DH; D'Amico TA; Pappas TN; Seigler HF; Wolfe WG; Tyler DS
    Ann Surg Oncol; 2006 Mar; 13(3):340-6. PubMed ID: 16485154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.
    Luu TD; Gaur P; Force SD; Staley CA; Mansour KA; Miller JI; Miller DL
    Ann Thorac Surg; 2008 Apr; 85(4):1217-23; discussion 1223-4. PubMed ID: 18355499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome.
    Wu TT; Chirieac LR; Abraham SC; Krasinskas AM; Wang H; Rashid A; Correa AM; Hofstetter WL; Ajani JA; Swisher SG
    Am J Surg Pathol; 2007 Jan; 31(1):58-64. PubMed ID: 17197919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus.
    Rohatgi PR; Swisher SG; Correa AM; Wu TT; Liao Z; Komaki R; Walsh G; Vaporciyan A; Lynch PM; Rice DC; Roth JA; Ajani JA
    Cancer; 2005 Oct; 104(7):1349-55. PubMed ID: 16130133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation.
    Wang KL; Yang Q; Cleary KR; Swisher SG; Correa AM; Komaki R; Ajani JA; Rashid A; Hamilton SR; Wu TT
    Cancer; 2006 Oct; 107(7):1467-74. PubMed ID: 16955509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followed by surgery or surgery alone.
    Kesler KA; Helft PR; Werner EA; Jain NP; Brooks JA; DeWitt JM; Leblanc JK; Fineberg NS; Einhorn LH; Brown JW
    Ann Thorac Surg; 2005 Apr; 79(4):1116-21. PubMed ID: 15797035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative chemoradiation therapy does not improve early survival after esophagectomy for patients with clinical stage III adenocarcinoma of the esophagus.
    Donington JS; Miller DL; Allen MS; Deschamps C; Nichols FC; Pairolero PC
    Ann Thorac Surg; 2004 Apr; 77(4):1193-8; discussion 1198-9. PubMed ID: 15063233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
    Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
    Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.
    Rizk NP; Venkatraman E; Bains MS; Park B; Flores R; Tang L; Ilson DH; Minsky BD; Rusch VW;
    J Clin Oncol; 2007 Feb; 25(5):507-12. PubMed ID: 17290058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation.
    Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Saltz LB; Goodman KA; Minsky BD; Wong WD; Weiser MR
    Cancer; 2008 Jul; 113(1):57-64. PubMed ID: 18442099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma.
    Rohatgi PR; Mansfield PF; Crane CH; Wu TT; Sunder PK; Ross WA; Morris JS; Pisters PW; Feig BW; Gunderson LL; Ajani JA
    Cancer; 2006 Oct; 107(7):1475-82. PubMed ID: 16944539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
    Brücher BL; Becker K; Lordick F; Fink U; Sarbia M; Stein H; Busch R; Zimmermann F; Molls M; Höfler H; Siewert JR
    Cancer; 2006 May; 106(10):2119-27. PubMed ID: 16607651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.
    Tong DK; Law S; Kwong DL; Chan KW; Lam AK; Wong KH
    Ann Surg Oncol; 2010 Aug; 17(8):2184-92. PubMed ID: 20217248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
    Kuo LJ; Liu MC; Jian JJ; Horng CF; Cheng TI; Chen CM; Fang WT; Chung YL
    Ann Surg Oncol; 2007 Oct; 14(10):2766-72. PubMed ID: 17551794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival.
    Berger AC; Farma J; Scott WJ; Freedman G; Weiner L; Cheng JD; Wang H; Goldberg M
    J Clin Oncol; 2005 Jul; 23(19):4330-7. PubMed ID: 15781882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.